13F Holdings
中文EN

FATE FATE THERAPEUTICS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1434316 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.4%
TTM net income YoY20.3%
TTM EPS YoY22.6%
Revenue 3-yr CAGR-64.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,760.0%
Net margin-2,619.6%
FCF margin-2,249.4%
EBITDA margin-2,519.2%

Returns

ROE-67.8%
ROA-42.8%
ROIC (approx.)-73.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets44.2%
Debt / equity0.00x
Current ratio4.41x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue31.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.65M$13.63M$63.53M$96.30M$55.85M
R&D expense$107.83M$135.00M$172.60M$320.45M$215.52M
SG&A expense$46.52M$74.17M$81.45M$84.23M$57.32M
Operating income-$147.70M-$210.28M-$190.51M-$308.39M-$216.99M
Interest expense————$0
Income tax$2,000$0$0$0$0
Net income-$136.31M-$186.26M-$160.93M-$281.72M-$212.15M
EBITDA-$134.80M-$191.31M-$172.23M-$294.63M-$211.14M
EPS (basic)-1.15-1.64-1.64-2.91-2.24
EPS (diluted)-1.15-1.64-1.64-2.91-2.24
Weighted avg. shares (diluted)118.79M113.69M98.41M96.83M94.75M
Balance sheet
Cash & equivalents$46.63M$36.06M$41.87M$61.33M$133.58M
Short-term investments$157.03M$243.01M$273.31M$374.89M$482.33M
Receivables$916,000$3.54M$1.83M$38.48M$8.68M
Current assets$208.70M$291.91M$331.54M$502.07M$633.41M
PP&E, net$56.92M$64.38M$96.84M$110.02M$91.53M
Total assets$318.94M$440.69M$506.22M$705.56M$921.46M
Current liabilities$36.07M$38.52M$39.09M$114.05M$81.28M
Total liabilities$111.75M$121.97M$137.80M$221.62M$242.62M
Shareholders' equity$207.18M$318.73M$368.42M$483.94M$678.84M
Shares outstanding115.36M113.93M98.63M97.29M95.73M
Cash flow statement
Operating cash flow-$106.08M-$122.87M-$132.26M-$248.21M-$162.87M
Capital expenditure$5.95M$730,000$6.15M$35.57M$50.70M
Free cash flow-$112.04M-$123.60M-$138.42M-$283.77M-$213.57M
Investing cash flow$111.17M$12.22M$112.67M$166.75M-$324.02M
Financing cash flow$5.49M$99.89M$85,000$9.21M$453.13M
Depreciation & amortization$12.90M$18.96M$18.28M$13.76M$5.85M
Stock-based compensation$24.92M$41.50M$43.46M$78.73M$54.36M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.